Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 7, 2003, Pages 763-770

  Koyama, Shohei ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Apoptosis; Chronic gastritis; DcR2; DR4; DR5; Flow cytometry; Helicobacter pylori; Tumor necrosis factor related apoptosis inducing ligand; Tumor necrosis factor related apoptosis inducing ligand receptors

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL SURFACE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 2; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA NUCLEOTIDYLEXOTRANSFERASE; LYMPHOCYTE ANTIGEN; PADGEM PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLOW CYTOMETRY; GASTRITIS; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL MUCOSA; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; NICK END LABELING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STOMACH EPITHELIUM; STOMACH MUCOSA; T LYMPHOCYTE;

EID: 0042031469     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03055.x     Document Type: Article

References (29)

1. Rudi J, Kuck D, Strand S et al. Involvement of the CD95 (Apo-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J. Clin. Invest. 1998; 102: 1506-14.
2. Koyama S. Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: Human glandular stomach as a site of immune privilege. Dig. Dis. Sci. 2000; 45: 773-80.
3. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Morre A, Askenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996; 271: 687-90.
5. Jo M, Kim T-H, Seol D-W et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Med. 2000; 6: 564-7.
6. Leverkus M, Neumann M, Mengling T et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000; 60: 553-9.
7. Nesterov A, Ivashchenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 2002; 21: 1135-40.
8. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821-30.
9. Pan GK, O'Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-13.
10. Scneider P, Thome M, Burns K et al. TRAIL receptor 1 (DR4) and 2 (DRS) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831-6.
11. Degli-Esposti MA, Dougall WC, Smolak PJ et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 1997; 7: 813-20.
12. Degli-Esposti MA, Smolak PJ, Walczak H et al. Cloning and characterization of TRAIL-R3, a novel member of the emergingTRAIL receptor family. J. Exp. Med. 1997; 186: 1165-70.
13. Frank S, Köhler U, Schackert G, Schackert HK. Expression of TRAIL and its receptors in human brain tumors. Biochem. Biophys. Res. Commun. 1999; 257: 454-9.
14. Fan XJ, Chua A, Shahi CN, McDevitt J, Keeling PWN, Kelleher D. Gastric T lymphocyte responses to Helicobacter pylori in patients with H. pylori colonization. Gut 1994; 35: 1379-84.
15. Bamford KB, Fan XJ, Crowe SE et al. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998; 114: 482-92.
16. Agnihotori N, Bhasin DK, Vohra H, Ray P, Singh K, Ganguly NK. Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori in patients. Scand. J. Gastroenterol. 1998; 33: 704-9.
17. - B cells are found in H. pylori-infected gastric mucosa. Am J. Gastroenterol. 1998; 93: 579-83.
18. Koyama S, Maruyama T, Adachi S, Nozue M. Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J. Cancer Res. Clin. Oncol. 1998; 124: 383-8.
19. Koyama S, Maruyama T, Adachi S. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. J. Cancer Res. Clin. Oncol. 1999; 125: 47-54.
20. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape by gastric carcinoma. J. Cancer Res. Clin. Oncol. 2001; 127: 20-6.
21. Koyama S, Koike N, Adachi S. Expression of TNF-related apoptosis inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol. 2002; 128: 73-9.
22. Satoh K, Kimura K, Taniguchi Y et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and assessment of the extent of atrophic gastritis. Am. J. Gastroenterol. 1998; 93: 569-73.
23. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. Am. J. Surg. Pathol 1996; 20: 1161-81.
24. Koyama S. Augmented human-tumor-cytotoxic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma. J. Cancer Res. Clin. Oncol. 1997; 123: 478-84.
25. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J. Immunol. 2000; 164: 3961-70.
26. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells. A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 1999; 189: 1451-60.
27. Steininger H, Faller G, Dewald E, Brabletz T, Jung A, Kirchner T. Apoptosis in chronic gastritis and its correlation with antigastric autoantibodies. Virchows Arch. 1998; 433: 13-18.
28. Scotiniotis IA, Rokkas T, Furth EE, Rigas B, Shift SJ. Altered gastric epithelial cell kinetics in Helicobacter pylori-associated intestinal metaplasia: Implications for gastric carcinogenesis. Int. J. Cancer 2000; 85: 192-200.
29. Zavros Y, Antwerp MV, Merchant JL. Use of flow cytometry to quantify mouse gastric epithelial cell populations. Dig. Dis. Sci. 2000; 45: 1192-9.